-
Risk Factors Analysis Related to Complications of Transrectal Ultrasound-Guided Prostate Needle Biopsy: The Influence of Asymptomatic Pyuria on Complications
-
Chae Han Jeon, Wonho Jung, Ji Yong Ha, Choal Hee Park, Chun Il Kim, Byung Hoon Kim
-
Korean J Urogenit Tract Infect Inflamm 2015;10(1):31-35. Published online April 30, 2015
-
-
-
 Abstract
 PDF
- Purpose: In clinical settings, patients with asymptomatic pyuria were common undergoing transrectal ultrasonography prostate needle biopsy (TRUSBx). The purpose of this study was to analyze the effects of asymptomatic pyuria on the occurrence of complications of TRUSBx. Materials and Methods: A total of 1,054 patients underwent TRUSBx from January 2007 to December 2011. For these patients, complications, presence of asymptomatic pyuria, anti-coagulant usage, TRUSBx history, previous hospitalization within 1 month, prostate volume, diabetes, types of prophylactic antibiotics (quinolone or 3rd generation cephalosporin), and biopsy results were compared and analyzed. Results: Of 1,054 cases, 26 (2.5%) developed complications requiring treatment. Seven cases (0.7%) had gross hematuria, 10 cases (0.9%) had dysuria, 7 cases (0.7%) had acute urinary retention, and 2 cases (0.2%) had sepsis. Asymptomatic pyuria was shown in 353 cases (33.4%). Complication rate of asymptomatic pyuria cases was 4.2% compared with 1.6% for non-pyuria cases (p=0.011). Higher complication rate was also observed in cases with previous TRUSBx history (p<0.001), hospitalization within 1 month (p< 0.001), and diabetes (p<0.001). However prostate volume, use of anticoagulant, type of antibiotics, and presence of prostate cancer were not significantly different. In multivariate analysis, previous TRUSBx history, hospitalization within 1 month, and diabetes were statistically significant with higher complication rate. Conclusions: A high incidence of complications was observed for previous TRUSBx history, hospitalization within 1 month, and diabetes. In univariate analysis, a high incidence of complications was observed for asymptomatic pyuria cases. Therefore, detailed caution is required for patients with such factors during TRUSBx.
-
Multicenter Clinical Outcome of Gatifloxacin for Chronic Prostatitis (NIH Category II or IIIa) in Korea
-
Sang Don Lee, Seung Ju Lee, Tae Kon Hwang, Duck Ki Yoon, Kyu Sung Lee, Luck Hee Sung, Myung Soo Choo, Bong Suk Shim, In Rae Cho, Min Eui Kim, Soo Bang Ryu, Chul Sung Kim, Young Gon Kim, Chun Il Kim, Hyun Yul Rhew, Yong-Hyun Cho
-
Korean J Urogenit Tract Infect Inflamm 2007;2(1):53-60. Published online May 31, 2007
-
-
-
Abstract
PDF
- "Purpose: The objective of this study was to investigate the efficacy and safety of gatifloxacin for patients with chronic prostatitis (NIH category II or IIIa) in Korean urologic practice. Materials and Methods: A total of 16 outpatient urology clinics at tertiary care medical centers in Korea participated. Gatifloxacin (400 mg/day) treatment (S.D.) of 149 patients (20 patients with category II and 129 patients with category IIIa) with prostatitis (mean age 45.8±13.3 years) was carried out for 41.7 (33.1) days. A 4-glass test according to Meares and Stamey or two glass test was carried out at study entry and one month after the end of treatment. Clinical response, safety and bacteriological response were assessed before treatment (within 48 hours of initiation of the study medication) and at one month after treatment completion. Results: In a otal of 149 patients, the total NIH-CPSI score was significantly reduced from 20.5 to 10.0 (response rate 86.7%; 95% CI 80.2-93.2%) (p<0.05). Sub-scores of pain, urinary symptoms and impact on the quality of life were also significantly reduced from 8.9 to 3.8 (response rate 83.8%; 95% CI 76.8-90.9%), from 4.2 to 2.0 (response rate 73.3%; 95% CI 64.9-81.8%) and from 7.4 to 4.2 (response rate 79.0%; 95% CI 71.3-86.8%), respectively (p<0.05). In terms of the overall clinical efficacy assessment by investigators, out of 149 patients with prostatitis, 71.2% were assessed to be responders. Bacteriological studies in expressed prostatic secretion (EPS) or post prostate massage urine (VB3) at 1 month after treatment completion demonstrated that the overall eradication rates of pathogens was 85% and the pyuria (≥10 WBC/HPF) rates in the NIH category II and IIIa were 35% and 18.6%, respectively (overall rate 20.8%). There were 16.1% of patients that presented with some adverse events considered by investigators to be related to the drug. The majority of adverse events were considered to be of mild (87.5%) or moderate (8.3%) intensity. Conclusions: These results suggest that gatifloxacin in Korean urologic practice is well tolerated and improves the clinical outcomes in the patientswith chronic prostatitis (NIH category II or IIIa)."
|
KAUTI
